new jersey- Page 983

Suburban Propane Announces the Commercial Launch of Propane+rDME, a Revolutionary Low-Carbon Fuel

Jubilant Therapeutics Inc. administre une dose au premier patient de l’essai de phase I/II évaluant le JBI-802, un inhibiteur double de LSD1 et de HDAC6, chez des patients atteints de tumeurs solides avancées Deutschland – Deutsch USA – English France – Français

PBF Logistics Declares Quarterly Distribution of $0.30 per Unit and Announces First Quarter 2022 Earnings Results

PBF Energy Announces First Quarter 2022 Results

LAWSUIT AGAINST DUNKIN’ BELIEVED TO BE FIRST ALLEGING LINK BETWEEN SEVERE CUSTOMER BURNS AND DEFECTIVE PAPER COFFEE-CUP CARRIER

Dstillery Launches ID-free Custom AI™ to Help Brands Reach Their Audiences Without Third-Party Cookies

COLOMBIAN AUTHOR AND CEO OF IVOICE COMMUNICATIONS ADRIANA ARISTIZÁBAL RELEASES THE SPANISH VERSION OF HER BOOK AT THE 34TH ANNUAL INTERNATIONAL BOOK FAIR HELD IN BOGOTÁ

“The Dog Dilemma!” Helps Families Prepare for Pet Adoption

Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation

Bausch + Lomb Corporation Announces Launch of IPO and Roadshow

Ocean County Man Admits Illegally Possessing Short-Barreled Rifle, Silencer, and Fake Federal Identification Badges

Somerset County Man Admits Conspiring to Distribute over 18 Kilograms of Heroin

Toms River Police Department Says Cops Can’t Smoke Weed Off Hours as State Weed War Rages

FirstEnergy Teams with Herbert Henderson Office of Minority Affairs

Met-Ed Green Team to Celebrate Arbor Day with Tree Planting in Reading

Capital One Reports First Quarter 2022 Net Income of $2.4 billion, or $5.62 per share

NIM Group to Acquire Plateplus, Inc.’s Tulsa, Oklahoma Plant

PEOPLES FINANCIAL SERVICES CORP. Reports First Quarter 2022 Earnings

INNOVATIVE INDUSTRIAL PROPERTIES, INC. (NYSE: IIPR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Innovative Industrial Properties, Inc. (NYSE: IIPR)

Jubilant Therapeutics Inc. verabreicht beim ersten Patienten die Dosis für die Phase I/II-Studie zur Untersuchung von JBI-802, einem dualen Inhibitor von LSD1 und HDAC6, bei Patienten mit fortgeschrittenen soliden Tumoren USA – English Deutschland – Deutsch